Doxorubicin

Generic Name
Doxorubicin
Brand Names
Adriamycin, Doxil, Myocet, Caelyx pegylated liposomal, Zolsketil pegylated liposomal, Myocet liposomal (previously Myocet), Celdoxome pegylated liposomal
Drug Type
Small Molecule
Chemical Formula
C27H29NO11
CAS Number
23214-92-8
Unique Ingredient Identifier
80168379AG
Background

Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970. Although they both have aglyconic and sugar moieties, doxorubicin's side chain terminates with a primary alcohol group compared to the methyl group of daunorubicin. Although its deta...

Indication

Doxorubicin is indicated for the treatment of neoplastic conditions like acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin and non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms’ tumor, metastatic neuroblastoma, metastatic soft tissue and bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinom...

Associated Conditions
AIDS-related Kaposi's Sarcoma, Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Advanced Endometrial Cancer, Advanced Ovarian Cancer, Breast Cancer, Hodgkin's Lymphoma, Metastatic Bone Sarcomas, Metastatic Breast Cancer, Metastatic Soft Tissue Sarcoma, Metastatic Thyroid Cancer, Metastatic Urothelial Cancer, Multiple Myeloma (MM), Mycosis Fungoides (MF), Non-Hodgkin's Lymphoma (NHL), Sezary Syndrome, Waldenström's Macroglobulinemia (WM), Advanced Thymoma, Advanced uterine sarcoma, Metastatic Bronchogenic Carcinoma, Metastatic Gastric carcinoma, Metastatic Neuroblastoma, Metastatic Ovarian carcinoma, Metastatic Wilms' tumor
Associated Therapies
-
Clinical Trials
Related News

Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas

First Posted Date
2024-05-21
Last Posted Date
2024-12-20
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
180
Registration Number
NCT06422806
Locations
🇺🇸

Keck Medicine of USC Koreatown, Los Angeles, California, United States

🇺🇸

Los Angeles General Medical Center, Los Angeles, California, United States

🇺🇸

USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States

and more 135 locations

QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk ER+/HER2- Breast Cancer

First Posted Date
2024-05-08
Last Posted Date
2024-05-08
Lead Sponsor
Fudan University
Target Recruit Count
76
Registration Number
NCT06404463

A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)

First Posted Date
2024-05-06
Last Posted Date
2024-12-20
Lead Sponsor
Children's Oncology Group
Target Recruit Count
1656
Registration Number
NCT06401330

SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer

First Posted Date
2024-05-01
Last Posted Date
2024-08-09
Lead Sponsor
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Target Recruit Count
440
Registration Number
NCT06394492
Locations
🇨🇳

Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

🇨🇳

National Cancer Center/Tumor Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China

A Study of BV-AVD in People With Bulky Hodgkin Lymphoma

First Posted Date
2024-04-22
Last Posted Date
2024-12-18
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
71
Registration Number
NCT06377566
Locations
🇺🇸

University of Miami, Miami, Florida, United States

🇺🇸

Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey, United States

🇺🇸

Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown, New Jersey, United States

and more 5 locations

A Trial of Cadonilimab With Adriamycin in Patients With Advanced Soft Tissue Sarcoma

Phase 2
Not yet recruiting
Conditions
Advanced Soft-tissue Sarcoma
Interventions
Drug: Cadonilimab
Drug: Adriamycin
First Posted Date
2024-04-16
Last Posted Date
2024-04-16
Lead Sponsor
Wuhan Union Hospital, China
Target Recruit Count
53
Registration Number
NCT06367075

Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma

First Posted Date
2024-04-10
Last Posted Date
2024-12-18
Lead Sponsor
Celgene
Target Recruit Count
850
Registration Number
NCT06356129
Locations
🇺🇸

Cancer Care Specialists, Reno, Nevada, United States

🇺🇸

Local Institution - 0498, East Brunswick, New Jersey, United States

🇺🇸

Moffitt Cancer Center, Tampa, Florida, United States

and more 344 locations

A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

Phase 3
Not yet recruiting
Conditions
Endometrial Cancer
Interventions
Drug: BNT323/DB-1303
Drug: Doxorubicin
Drug: Paclitaxel
First Posted Date
2024-04-01
Last Posted Date
2024-12-20
Lead Sponsor
BioNTech SE
Target Recruit Count
468
Registration Number
NCT06340568

Ma-Spore ALL 2020 Study

First Posted Date
2024-03-28
Last Posted Date
2024-03-28
Lead Sponsor
National University Hospital, Singapore
Target Recruit Count
500
Registration Number
NCT06336395
Locations
🇲🇾

University Malaya Medical Centre, Kuala Lumpur, Malaysia

🇲🇾

Subang Jaya Medical Centre, Kuala Lumpur, Malaysia

🇸🇬

KK Women's and Children's Hospital, Singapore, Singapore

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

First Posted Date
2024-03-19
Last Posted Date
2024-12-04
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
171
Registration Number
NCT06317662
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy